Desomorphine

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Desomorphine
Accession Number
DB01531
Type
Small Molecule
Groups
Experimental, Illicit
Description
Not Available
Structure
Thumb
3D
Similar Structures
Synonyms
  • 4,5-epoxy-3-hydroxy-n-methylmorphinan
  • 6-deoxy-7,8-dihydromorphine
  • Deoxydihydromorphine D
  • Dihydrodeoxymorphine
  • Dihydrodesoxymorphine D
External IDs
IDS-ND-002 / IDS-ND-002(SECT.3)
Categories
UNII
7OP86J5E33
CAS number
427-00-9
Weight
Average: 271.36
Monoisotopic: 271.15722892
Chemical Formula
C17H21NO2
InChI Key
LNNWVNGFPYWNQE-GMIGKAJZSA-N
InChI
InChI=1S/C17H21NO2/c1-18-8-7-17-11-3-2-4-14(17)20-16-13(19)6-5-10(15(16)17)9-12(11)18/h5-6,11-12,14,19H,2-4,7-9H2,1H3/t11-,12+,14-,17+/m0/s1
IUPAC Name
(1S,5R,13S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-trien-10-ol
SMILES
[H][C@@]12CCC[C@@]3([H])[C@@]4([H])CC5=CC=C(O)C(O1)=C5[C@@]23CCN4C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Unlock Additional Data
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Desomorphine.
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Desomorphine.
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Desomorphine.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Desomorphine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Desomorphine is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Desomorphine is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Desomorphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
AcepromazineThe risk or severity of hypotension and CNS depression can be increased when Acepromazine is combined with Desomorphine.
AceprometazineThe risk or severity of hypotension and CNS depression can be increased when Aceprometazine is combined with Desomorphine.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Desomorphine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5362456
PubChem Substance
46506785
ChemSpider
4515044
ChEBI
135119
ChEMBL
CHEMBL2106274
Wikipedia
Desomorphine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.86 mg/mLALOGPS
logP2.5ALOGPS
logP2.11ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)10.35ChemAxon
pKa (Strongest Basic)9.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.7 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity77.8 m3·mol-1ChemAxon
Polarizability29.99 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9976
Caco-2 permeable+0.8647
P-glycoprotein substrateSubstrate0.7728
P-glycoprotein inhibitor INon-inhibitor0.8039
P-glycoprotein inhibitor IINon-inhibitor0.9509
Renal organic cation transporterInhibitor0.6957
CYP450 2C9 substrateNon-substrate0.7987
CYP450 2D6 substrateSubstrate0.8615
CYP450 3A4 substrateSubstrate0.7723
CYP450 1A2 substrateNon-inhibitor0.753
CYP450 2C9 inhibitorNon-inhibitor0.9425
CYP450 2D6 inhibitorInhibitor0.5254
CYP450 2C19 inhibitorNon-inhibitor0.7726
CYP450 3A4 inhibitorNon-inhibitor0.7977
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9193
Ames testNon AMES toxic0.6475
CarcinogenicityNon-carcinogens0.9564
BiodegradationNot ready biodegradable0.9841
Rat acute toxicity3.0641 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7496
hERG inhibition (predictor II)Non-inhibitor0.8412
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.57 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Tetralins / Coumarans / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / Oxacyclic compounds / Azacyclic compounds
show 2 more
Substituents
Morphinan / Phenanthrene / Tetralin / Coumaran / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Benzenoid / Tertiary amine
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on July 31, 2007 07:10 / Updated on August 02, 2019 06:51